

Management of *Helicobacter pylori* infection: the Maastricht VI/Florence consensus report

Peter Malfertheiner

Standards and Guidelines

Stomach & H. Pylori

August 8, 2022

The sixth Maastricht/Florence 2021 Consensus Report updates recommendations for managing *Helicobacter pylori* infection, now formally recognised as an infectious disease in ICD-11, with a recommendation that all infected patients receive treatment.

KEY POINTS

- Forty-one experts from 29 countries re-evaluated key aspects of *H. pylori* infection across five working groups covering indications/associations, diagnosis, treatment, prevention/gastric cancer, and gut microbiota effects
- Rising antibiotic resistance challenges *H. pylori* treatment and requires susceptibility testing with consideration of novel molecular technologies and careful selection of first-line and rescue therapies
- The report addresses identification of distinct clinical scenarios, proper testing, and strategies for prevention of gastric cancer and other complications associated with *H. pylori* gastritis
- Recommendations are based on best available evidence for managing *H. pylori* infection across various clinical fields, with consideration of the impact of *H. pylori* and antibiotic therapies on gut microbiota

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/d0982e90-abe0-11ef-a3e3-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.